CSF2 and melanoma: In view of the fact that GM‐CSF is used as an adjuvant in various cancer immunotherapy trials (including melanoma) [8], it would be of great benefit to exclude patients bearing tumors whose malignancy may be enhanced by GM‐CSF treatment from this therapy modality.